Biotinoyl Tripeptide-1

This is Gly-His-Lys with biotin conjugated to the N-terminal amine. The GHK part supplies matrikine signalling to the perifollicular connective tissue — collagen IV and laminin-5 at the dermal sheath are what physically anchor a follicle — while biotin conjugation is intended to improve delivery and add a keratin-relevant cofactor at the site. It is the peptide component of Procapil, a three-part complex that also contains apigenin, a citrus flavonoid that improves microcirculation, and oleanolic acid, which inhibits 5-alpha-reductase. When people credit 'Procapil' with anti-DHT activity, they are crediting oleanolic acid, not this peptide. On its own the peptide's contribution is anchoring and matrix, not androgen blockade.

Targets: Perifollicular collagen IV and laminin-5, Dermal sheath adhesion, Hair follicle anchoring

• · As part of Procapil, 3% of the finished formula is the standard use level. As an isolated peptide, 0.01-0.05% w/w in an aqueous or hydroalcoholic scalp vehicle.

Work out your exact syringe units →

• rareScalp irritation— Usually the alcohol in the vehicle rather than the peptide.

• synergyahk-cu — Anchoring plus vascular signalling; a common scalp-serum combination.
• synergycapixyl — Matrix support plus 5-alpha-reductase inhibition.
• redundantghk-cu-topical — Same GHK backbone with a different conjugate.

• · Wash or pull counts to track shedding, plus fixed-area photographs at 0, 3 and 6 months.

Cosmetic ingredient (INCI Biotinoyl Tripeptide-1) approved worldwide.

• Sederma Procapil technical dossier (other)

The interesting question about this molecule is what the biotin is actually for, because two different answers circulate and only one of them holds up. The marketing answer is that biotin is a keratin-relevant cofactor delivered to the follicle. That is weak: biotin's role is as a cofactor for carboxylases in fatty acid synthesis and gluconeogenesis, biotin deficiency does cause alopecia but true deficiency is rare, and supplementing biotin in people who are not deficient has no good evidence for hair growth. The more defensible answer is that biotinylation is a delivery and stability modification — it caps the N-terminus against aminopeptidase attack and adds enough lipophilicity to improve partitioning, the same job palmitoylation does with less added mass. The peptide arm is more substantive. GHK signalling to perifollicular connective tissue raises collagen IV and laminin-332 at the dermal sheath, and those two proteins are literally what anchors a follicle mechanically into the dermis. Follicular anchoring is an underrated target: a follicle that releases its hair prematurely produces shedding independently of whether it is miniaturising. That is why the honest claim here is reduced shedding rather than increased density. The critical thing to get right is attribution within Procapil. Procapil is three components: biotinoyl tripeptide-1, apigenin (a citrus flavonoid improving microcirculation) and oleanolic acid (which inhibits 5-alpha-reductase). Every anti-DHT claim made for Procapil belongs to the oleanolic acid. The peptide does not touch androgens.

Attribution, and it is systematic. Almost everyone using this is using Procapil, almost every published dataset is on Procapil, and Procapil's most impressive property — 5-alpha-reductase inhibition — comes from oleanolic acid, not from the peptide. So the peptide gets credit for something it does not do. Second, endpoint confusion: this targets shedding and anchoring, and shedding is measured with wash counts or a standardised pull test, not by looking at your hairline. Someone tracking density will conclude it does nothing while the thing it might be doing goes unmeasured. Third, the biotin halo: people assume biotinoyl means a hair vitamin, and topical biotin has no meaningful evidence for hair growth in anyone who is not biotin deficient.

• Perifollicular collagen IV and laminin-332 — No receptor cloned; matrikine signalling as with the rest of the GHK family

  Strengthens the dermal sheath attachment of the follicle, which is the anti-shedding mechanism.

• Biotin-dependent carboxylases (claimed) — Not a receptor interaction

  The keratin-cofactor rationale. Weak — biotin supplementation does not help hair in people who are not deficient.

• Samadi et al. topical caffeine plus Procapil 3% in male pattern hair loss (J Cosmet Dermatol) Clinical efficacy and tolerability study · 2024

  Efficacy and tolerability of a combined caffeine plus Procapil formulation for male pattern hair loss. Procapil rather than the isolated peptide, and combined with caffeine, so attribution is limited.

• Comparative study of topical Procapil with platelet-rich plasma versus topical Redensyl with PRP (Cureus) Comparative clinical study · 2023

  Head-to-head comparison of two topical hair actives as PRP adjuncts. Again Procapil rather than the isolated peptide.

Month 2-3: reduced shedding, measurable by wash count. Month 6: density change if any, which is a much weaker expectation than the shedding effect. Nothing before eight weeks is real.

AHK-Cu is the conventional partner — vascular support plus anchoring — and Capixyl adds the anti-androgen arm this peptide lacks entirely. That three-way combination covers vasculature, matrix and DHT, which is a coherent topical strategy even though each component individually has thin evidence. Caffeine is the partner with published human data alongside it. There is no chemical incompatibility with anything; unlike GHK-Cu there is no copper to protect. The important framing point: this peptide is a supporting act. It does not address androgen-driven miniaturisation, which is the actual disease process in androgenetic alopecia, so it belongs alongside minoxidil or an anti-androgen rather than instead of one.

Against AHK-Cu, both are GHK-family scalp peptides — this one targets anchoring, AHK-Cu targets vasculature, and AHK-Cu has the human follicle organ culture data. Against Capixyl, Capixyl has the randomised placebo-controlled study and an actual anti-androgen mechanism, which makes it the better single choice. Against minoxidil or finasteride, not a serious comparison. The distinctive thing about this peptide is that Procapil has accumulated several independent indexed clinical studies, which is unusual in this class — even if none of them isolates the peptide.

$10–$50/month. Raw biotinoyl tripeptide-1 runs roughly $40-90 per gram at 0.01-0.05% use levels. Procapil-containing scalp serums $15-50 a month. Market observation, not a sourced pricing study.

• ?No study has ever tested biotinoyl tripeptide-1 in isolation on human scalp. All human data are on the Procapil complex.
• ?The biotinidase-mediated prodrug hypothesis — that skin biotinidase releases free GHK and biotin — is a reasonable inference from known enzymology and has not been demonstrated for this molecule.
• ?The collagen IV and laminin-332 anchoring claims come from supplier work I could not resolve to a primary indexed publication.
• ?No permeation data exist.
• ?The molecular weight of 566.7 Da in the Core record is plausible for biotinyl-GHK but is unconfirmed against a primary source.
• ?Whether the biotin conjugation contributes anything beyond N-terminal protection and lipophilicity is unknown.

• Assessment of the efficacy and tolerability of a topical formulation containing caffeine and Procapil 3% for improvement of male pattern hair loss Samadi A, Rokhsat E, Saffarian Z, Goudarzi MM, Kardeh S, Nasrollahi SA, Firooz A, Journal of Cosmetic Dermatology, 2024 · PMID 37990760

  Indexed human data on a Procapil-containing formulation, from an independent academic dermatology group in Tehran.

• A Comparative Study of Topical Procapil With Platelet-Rich Plasma Therapy Versus Topical Redensyl With Platelet-Rich Plasma Therapy Tr P, et al., Cureus, 2023 · PMID 37292551

  Independent comparative clinical work on Procapil.

• Comparison of Platelet Rich Therapy Alone With Platelet Rich Therapy Along With Daily Topical 5% Procapil Khoso H, Fahim M, Journal of Ayub Medical College Abbottabad, 2024 · PMID 39609969

  Adds Procapil to PRP and measures the increment, which is the closest thing to an isolated test of the complex.

• Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data Pickart L, Margolina A, International Journal of Molecular Sciences, 2018 · PMID 29986520

  Background on the GHK backbone and its effects on collagen IV and laminin, which is the anchoring mechanism claimed here.

• Overview of Short Peptides for Hair Loss Fan C, Chen Y, Huang Q, Ou WY, Zhang C, Sun Y, Wu T, Leung OY, Iu HC, Shi J, Biomedicines, 2026 · PMID 42072405

  Recent review of the peptide hair-loss landscape.